Granulomas are collections of activated macrophages (epithelioid cells) often with multinucleated giant cells and surrounding lymphocytes, representing a protective response to persistent antigen or irritant that cannot be cleared. Classic causes include tuberculosis, fungal infections, and sarcoidosis. Formation requires Th1/Th17 responses and IL-12/IFN-γ signaling. While compartmentalizing infection or irritant, granulomas can impair organ function and release inflammatory mediators causing systemic effects.
Study caseating granulomas in TB (with central necrosis) versus non-caseating in sarcoidosis and fungal disease. Understand the role of Th1 immunity in granuloma formation. Consider granulomas as evidence of chronic antigenic stimulation.
Not all granulomas contain giant cells; giant cells form from fusion of epithelioid cells but are not required for the diagnosis. Granulomatous inflammation is not synonymous with granulomatous disease; some granulomas are appropriately protective.
From your study of chronic inflammation, you know that the macrophage is the central effector cell of sustained inflammatory responses—it can be activated to different functional states, releases cytokines that orchestrate the local milieu, and can persist at sites of tissue damage for weeks to months. Granuloma formation is the endpoint that chronic inflammation reaches when macrophages encounter something they cannot destroy or clear: a persistent antigen that is too large or too resistant for individual macrophage digestion. The granuloma is essentially a cell-mediated walling-off strategy—the immune system's attempt to contain what it cannot eliminate.
The formation process begins with macrophage activation by a poorly degradable stimulus—classically the waxy lipid-rich cell wall of Mycobacterium tuberculosis, the cell wall components of certain fungi (Histoplasma, Coccidioides), or the insoluble particles in sarcoidosis. Antigen-presenting cells present fragments of the pathogen to T helper cells, which differentiate into a Th1 phenotype under the influence of IL-12 secreted by macrophages. Th1 cells then release IFN-γ, which drives macrophages into a highly activated state and induces them to fuse or to transform into epithelioid cells—macrophages with abundant cytoplasm and close cell-to-cell contacts that resemble epithelial cells under the microscope, hence the name. When multiple epithelioid cells fuse their membranes together, they form multinucleated giant cells with up to dozens of nuclei—a morphological hallmark of granulomatous inflammation that you can use as a diagnostic anchor. The whole structure is reinforced by a rim of lymphocytes (primarily CD4+ T cells) that maintain the Th1 cytokine environment, and fibroblasts that deposit collagen around the periphery.
The most clinically important distinction in granuloma pathology is between caseating and non-caseating granulomas. In tuberculosis, the center of the granuloma undergoes a distinctive form of necrosis—caseous necrosis, named for its cheese-like gross appearance—resulting from macrophage death, the toxic products of activated complement, and lysosomal enzyme release. Non-caseating granulomas (in sarcoidosis, berylliosis, Crohn's disease, and many fungal infections) lack this central necrosis. The presence or absence of caseation is a major clue to etiology: caseating granulomas almost always point to tuberculosis or atypical mycobacteria, while non-caseating granulomas have a broader differential diagnosis. On slides, you identify this by looking for pink amorphous material at the granuloma center surrounded by epithelioid macrophages—a pattern that should immediately prompt you to consider TB.
The functional cost of granulomatous inflammation reveals an important principle from your prior study of inflammatory mediators: the cytokines maintaining the granuloma are not targeted at the granuloma alone. TNF-α, secreted abundantly by activated macrophages within granulomas, is essential for granuloma integrity—this is why TNF inhibitors used in rheumatoid arthritis and IBD treatment carry a risk of reactivating latent TB by disrupting established granulomas, allowing previously contained mycobacteria to disseminate. Granulomas in the lung (TB, sarcoidosis), liver (hepatic granulomas in schistosomiasis), or kidney can progressively impair organ function as fibrosis replaces functional parenchyma. The same immune architecture that successfully contains an infection can cause significant structural damage in the process—granulomatous inflammation is effective containment at the cost of local tissue destruction.
No topics depend on this one yet.